Single‐agent therapy has demonstrated efficacy in certain cases of recurrent T‐cell lymphoma (particularly ALK‐positive ALCL), with a median overall survival of up to 55 months; the overall response rate has not met expectations. Here, ALK is linked to anaplastic large cell lymphoma.